FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of biotechnology, namely to obtaining insulin analogues, and can be used in medicine as a medication for reducing the glucose level in a patient's blood. An insulin analogue contains a polypeptide B-chain, including halogenated phenylalanine in B24 position, which provides an increased stability in comparison with non-halogenated insulin or insulin analogue. Halogenated phenylalanine represents ortho-monofluorophenylalanine, ortho-monobromophenylalanine or ortho-monochlorophenylalanine.
EFFECT: halogenation-conditioned insulin stabilisation makes it possible to simplify the treatment of patients with diabetes mellitus in developing countries, where there is no access to refrigerating equipment.
11 cl, 8 dwg, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| INSULIN ANALOGUES CHARACTERIZED BY REDUCED AFFINITY OF BINDING TO INSULIN RECEPTORS | 2019 |
|
RU2816595C2 |
| INSULIN CONJUGATES | 2019 |
|
RU2809189C2 |
| INSULIN ANALOGUES | 2017 |
|
RU2769476C2 |
| INSULIN ANALOGUES WITH REDUCED AFFINITY TO INSULIN RECEPTOR AND THEIR USE | 2017 |
|
RU2764197C1 |
| INSULIN ANALOGUE COMPLEX WITH REDUCED AFFINITY TO INSULIN RECEPTOR AND ITS USE | 2018 |
|
RU2779462C2 |
| CONJUGATE OF LONG-ACTING PHYSIOLOGICALLY ACTIVE SUBSTANCE AND ITS USE | 2018 |
|
RU2773823C2 |
| BISPECIFIC ANTIBODY | 2019 |
|
RU2796019C2 |
| HUMAN INTERLEUKIN-2 VARIANT OR ITS DERIVATIVE | 2019 |
|
RU2799437C2 |
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
